CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| A052101 | Alliance | A Randomized Phase 3 Trial of Continuous vs Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| EAF223 | ECOG-ACRIN | Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE) | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GY021 | NRG | A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab In Platinum-Sensitive Recurrent Ovarian Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA2176 | ECOG-ACRIN | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients | Adult CIRB - Late Phase Emphasis | Available to Open |
| NSABP-B-38 | NSABP | A Phase III; Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG) | Adult CIRB - Late Phase Emphasis | Completed |
| RTOG-0924 | RTOG | Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA8192 | ECOG-ACRIN | A Phase II/III trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy | Adult CIRB - Late Phase Emphasis | Available to Open |
| S0106 | SWOG | A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML) | Adult CIRB - Late Phase Emphasis | Completed |
| ACOSOG-Z1031 | ACSOG | A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily); Letrozole (2.5 mg); or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| S9910 | SWOG | Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary | Adult CIRB - Late Phase Emphasis | Completed |